The Executive team has a proven track record in moving rapidly from scientific concepts to clinical development.

The achievement of our goals is largely driven by the competences and the skills of the ASIT biotech employees. Expertise, professional experience and commitment are at the heart of our business. It is through the dedicated work of ASIT biotech's teams that breakthrough allergy immunotherapy drugs are invented and further developed for commercialization.

Executive management team

Michel Baijot fddd0

Michel Baijot

Bioengineer, PhD, Michel Baijot is a life science executive bringing over 25 years of experience in building biologicals businesses with significant contribution in strategy, licensing, M&A and technology transfer.

His positions with biotech and big pharmaceutical companies as well as his tangible achievements reflect an in-depth knowledge of the business environment in both developed and emerging markets.

He is currently Board Director of IRE-Elit, the RadioPharma Division of IRE, and Board Director of OncoRadiomics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association during 5 years.

Frank Hazevoets 2 299f4

Frank Hazevoets

Master of Business Economics and Master of Engineering in Artificial Intelligence and Cognitive Science, Frank Hazevoets was investment banker at several banks such as ING and director of strategy and internal growth at AB Inbev before he became active in the healthcare sector in 2007 where he had CFO positions at Tigenix and Promethera Biosciences before joining Asit Biotech in April of 2019 as CFO.

Philippe Ghem 06fae

Philippe Ghem
Head of Commercial Operations & Licensing

Commercial Engineer from the Solvay Business School and holder of a license in Business and Marketing from HEC Saint Louis (now ICHEC, Brussels), Philippe Ghem brings over 20 years of commercial expertise in the pharmaceutical industry (retail, hospital, vaccines, devices) gained in sales and marketing positions of big pharma (ABBOTT, GSK, NOVARTIS) and specialty companies (COLOPLAST, GRUNENTHAL). In recent positions he was also regularly involved in Market Access and Business Development activities. Philippe Ghem joined ASIT Biotech in April 2018 as Chief Commercial Officer.

Vincent Bille 3 2095c

Vincent Bille
Head of Operations

Holder of a PhD in Biochemistry from the University of Namur and a Master in Business Administration (IAG) from the Catholic University of Louvain-La-Neuve, Vincent Bille started his career at UCB as Head of the Peptide Department within the contract manufacturing division and became Director Commercial Operations, North America and General Manager US. He was then Director Sales & Business Development for Lonza in the US and Europe. In 2007, he founded Marble Pharma Consult sprl which provides consultancy services in externalized development and manufacturing operations. Vincent Bille joined ASIT Biotech as Head of CMC in 2016 to manage the manufacturing of the ASIT products.

Sabine Pirotton 3 4f5b3

Sabine Pirotton
Project Manager

Holder of a PhD in Biochemistry from the Free University of Brussels, Sabine Pirotton joined ASIT Biotech in 2005 after 20 years as a Senior Scientist at the University of Brussels and Namur. She is a co-inventor of most of the patents filed by ASIT biotech. Today, Sabine Pirotton is Head of Research and Development, and continues to explore new promising drug candidates with her dedicated team.

ASIT Marie Pierre Beaumont 6c487

Marie Pierre Beaumont
Head of Human Resources

Marie Pierre has over 30 years’ experience in human resources. She spent most of her career working in retail companies, including GIB group and IKEA, but also spent some time as a self-employed consultant in human resources and social relations in smaller organizations. Marie has a degree in Psychology and Education Sciences from the University of Liège. She joined ASIT biotech in August 2019.

Rémy vF 40897

Rémy von Frenckell
Head of Clinical Development

Civil Engineer in Chemistry and holder of a PhD in Experimental Biomedical Sciences, Remy von Frenckell has more than 35 years of experience in drug development in Academia (University of Liège) and in the pharmaceutical industry (BMS, UCB). He has more than 150 publications in peer reviewed journals. In his extensive career and after 15 years in Academia, he started in the pharmaceutical industry as Associate Director Biostatistics and Data Management at BMS, then joined UCB as Vice-President Statistics, Data Management, Outcomes Research, and finally EORTC (European Organization for Research and Treatment of Cancer) as Director Methodology & Operations. Remy von Frenckell joined ASIT Biotech in November 2016 as a consultant and is now Head of Clinical Development.

 Martine Draguet 1 33c5a

Martine Draguet
Head of Regulatory Affairs and Quality Assurance

Pharmacist and Industrial Pharmacist (QP) from University of Louvain (UCL) in Belgium, and holder of a PhD from the University of Louvain, Martine Draguet brings 30 years of experience in Pharmaceutical Regulatory Affairs. After 10 years in academic research, she joined the pharmaceutical industry where she has developed and implemented International and Regional regulatory strategies for several blockbuster drug products. She has also been acting for several years as EFPIA topic leader in the Q4B group of ICH. Since 2010 as consultant, she helps pharmaceutical companies developing and/or implementing their regulatory/quality strategy. Martine Draguet joined ASIT Biotech in November 2014 as a consultant and is now Head of Regulatory Affairs and Quality Assurance.